EpiPharm Competitors and Similar CompaniesClear all

EpiPharm's competitors and similar companies include Mersana Therapeutics, Dendreon, Antikor and Century Therapeutics.

	EpiPharm EpiPharm is a biopharmaceutical company developing non-invasive products for the treatment of benign skin tumours and hyperpigmentation disorders.	Mersana Therapeutics Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms.	Dendreon Dendreon Pharmaceuticals (formerly known as Activated Cell Therapy) is a biopharmaceutical company that engages in the development of immunotherapy.	Antikor Antikor is a biotechnology company that specializes in the discovery and development of small-format antibody-drug conjugates.	Century Therapeutics Century Therapeutics is a biotech company that develops therapies to treat cancer.
Founding Date	Founding Date 2007	Founding Date 2005	Founding Date 1992	Founding Date 2014	Founding Date 2018
Type	Type Private	Type Public	Type Subsidiary	Type Private	Type Public
Tags	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy
Locations	Locations Binningen, CH HQ	Locations Cambridge, US HQ	Locations Seal Beach, US HQ Seattle, US Union City, US Tampa, US	Locations Stevenage, GB HQ	Locations Philadelphia, US HQ Hamilton, CA Seattle, US
Employees	Employees 4	Employees 11033% increase	Employees 6131% decrease	Employees 11	Employees 107
Valuation ($)	Valuation ($) N/A	Valuation ($) 250.3 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 115.2 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $40.5m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $109.2m (FY, 2025)
Net income	Net income N/A	Net income ($69.2m) (FY, 2024)	Net income N/A	Net income N/A	Net income ($9.6m) (FY, 2025)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 219.5m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 410m